fluoxetine has been researched along with Memory Disorders in 31 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 7.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| "Fluoxetine (FLX) is a common selective serotonin reuptake inhibitor, which is used in adolescents with psychiatric disorders." | 5.56 | Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level. ( Adak, O; Dehghany, R; Saadati, H; Sadegzadeh, F; Sakhaie, N, 2020) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 5.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "Fluoxetine is often prescribed to treat depression during pregnancy." | 4.02 | Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring. ( Ampuero, E; de Vries, EF; Díaz-Galarce, R; Donoso-Ramos, JP; Doorduin, J; Linsambarth, S; Moraga-Amaro, R; Pacheco, R; Peña, F; Stehberg, J; Ugalde, V; Wyneken, U, 2021) |
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 3.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| "Fluoxetine (FLX) is a common selective serotonin reuptake inhibitor, which is used in adolescents with psychiatric disorders." | 1.56 | Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level. ( Adak, O; Dehghany, R; Saadati, H; Sadegzadeh, F; Sakhaie, N, 2020) |
| "Vortioxetine is a multimodal-acting antidepressant that is hypothesized to exert its therapeutic activity through 5-HT reuptake inhibition and modulation of several 5-HT receptors." | 1.43 | Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. ( du Jardin, KG; Elfving, B; Liebenberg, N; Müller, HK; Sanchez, C; Wegener, G, 2016) |
| "VPA-treated rats showed memory deficits, a decrease in the number of proliferating cells in the sub granular zone and decreases in the levels of Notch1 and BDNF but not DCX compared to control animals." | 1.43 | Fluoxetine prevents the memory deficits and reduction in hippocampal cell proliferation caused by valproic acid. ( Chaijaroonkhanarak, W; Chaisawang, P; Pannangrong, W; Prachaney, P; Sangrich, P; Sirichoat, A; Welbat, JU; Wigmore, P, 2016) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 1.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "Fluoxetine was found to suppress neuronal cell loss when injected at 10 mg/kg and the effect was enhanced at 50 mg/kg." | 1.35 | Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. ( Han, PL; Jin, Y; Kim, SW; Lee, JK; Lim, CM; Park, JY; Seo, JS; Yoon, SH, 2009) |
| " We trained ADX and control rats in a moving, hidden platform version of the Morris water task before chronic administration (6 weeks) of CORT and either fluoxetine or vehicle." | 1.34 | Adrenalectomy-induced granule cell degeneration in the hippocampus causes spatial memory deficits that are not reversed by chronic treatment with corticosterone or fluoxetine. ( Epp, JR; Keith, JR; Spanswick, SC; Sutherland, RJ, 2007) |
| " Therefore, we studied the effects of long-term administration of fluoxetine on both spatial-reference memory and working memory, recovery of function after intrahippocampal colchicine infusions, which can destroy 50-70% of DG granule cells, and electrophysiological responses in the DG to perforant path stimulation in freely moving rats." | 1.34 | Fluoxetine and the dentate gyrus: memory, recovery of function, and electrophysiology. ( Epp, JR; Keith, JR; Sutherland, RJ; Wu, Y, 2007) |
| "Fluoxetine has a favorable adverse effect profile when compared with older classes of antidepressants." | 1.32 | Memory loss in a patient treated with fluoxetine. ( Burton, RM; Joss, JD; Keller, CA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Hosseinzadeh Sahafi, O | 1 |
| Rezayof, A | 1 |
| Ghasemzadeh, Z | 1 |
| Alijanpour, S | 1 |
| Rahimian, S | 1 |
| Zhou, Y | 1 |
| Tao, X | 1 |
| Wang, Z | 1 |
| Feng, L | 1 |
| Wang, L | 1 |
| Liu, X | 1 |
| Pan, R | 1 |
| Liao, Y | 1 |
| Chang, Q | 1 |
| Sadegzadeh, F | 1 |
| Sakhaie, N | 1 |
| Dehghany, R | 1 |
| Adak, O | 1 |
| Saadati, H | 1 |
| Moraga-Amaro, R | 1 |
| Díaz-Galarce, R | 1 |
| Donoso-Ramos, JP | 1 |
| Ugalde, V | 1 |
| Linsambarth, S | 1 |
| Doorduin, J | 1 |
| de Vries, EF | 1 |
| Ampuero, E | 1 |
| Peña, F | 1 |
| Pacheco, R | 1 |
| Wyneken, U | 1 |
| Stehberg, J | 1 |
| Gan, H | 1 |
| Zhang, Q | 1 |
| Zhu, B | 1 |
| Wu, S | 1 |
| Chai, D | 1 |
| Flores-Burgess, A | 1 |
| Millón, C | 1 |
| Gago, B | 1 |
| García-Durán, L | 1 |
| Cantero-García, N | 1 |
| Coveñas, R | 1 |
| Narváez, JA | 1 |
| Fuxe, K | 1 |
| Santín, L | 1 |
| Díaz-Cabiale, Z | 1 |
| Epelbaum, S | 1 |
| Dubois, B | 1 |
| Begenisic, T | 1 |
| Baroncelli, L | 1 |
| Sansevero, G | 1 |
| Milanese, M | 1 |
| Bonifacino, T | 1 |
| Bonanno, G | 1 |
| Cioni, G | 1 |
| Maffei, L | 1 |
| Sale, A | 1 |
| Lutz, PE | 1 |
| Ayranci, G | 1 |
| Chu-Sin-Chung, P | 1 |
| Matifas, A | 1 |
| Koebel, P | 1 |
| Filliol, D | 1 |
| Befort, K | 1 |
| Ouagazzal, AM | 1 |
| Kieffer, BL | 1 |
| Han, H | 1 |
| Dai, C | 1 |
| Dong, Z | 1 |
| Yun, HM | 1 |
| Park, KR | 1 |
| Kim, EC | 1 |
| Kim, S | 1 |
| Hong, JT | 1 |
| Luo, P | 1 |
| Zhang, X | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Li, C | 1 |
| Zhou, M | 1 |
| Lu, Q | 1 |
| Xu, X | 1 |
| Shen, G | 1 |
| Guo, L | 1 |
| du Jardin, KG | 1 |
| Liebenberg, N | 1 |
| Müller, HK | 1 |
| Elfving, B | 1 |
| Sanchez, C | 1 |
| Wegener, G | 1 |
| Welbat, JU | 1 |
| Sangrich, P | 1 |
| Sirichoat, A | 1 |
| Chaisawang, P | 1 |
| Chaijaroonkhanarak, W | 1 |
| Prachaney, P | 1 |
| Pannangrong, W | 1 |
| Wigmore, P | 2 |
| Jin, Y | 1 |
| Lim, CM | 1 |
| Kim, SW | 1 |
| Park, JY | 1 |
| Seo, JS | 1 |
| Han, PL | 1 |
| Yoon, SH | 1 |
| Lee, JK | 1 |
| ElBeltagy, M | 2 |
| Mustafa, S | 1 |
| Umka, J | 2 |
| Lyons, L | 2 |
| Salman, A | 1 |
| Chur-yoe, GT | 1 |
| Bhalla, N | 1 |
| Bennett, G | 2 |
| Wigmore, PM | 1 |
| Conboy, L | 1 |
| Varea, E | 1 |
| Castro, JE | 1 |
| Sakouhi-Ouertatani, H | 1 |
| Calandra, T | 1 |
| Lashuel, HA | 1 |
| Sandi, C | 1 |
| Bianchi, P | 1 |
| Ciani, E | 1 |
| Guidi, S | 1 |
| Trazzi, S | 1 |
| Felice, D | 1 |
| Grossi, G | 1 |
| Fernandez, M | 1 |
| Giuliani, A | 1 |
| Calzà, L | 1 |
| Bartesaghi, R | 1 |
| Markwick, R | 1 |
| Startin, C | 1 |
| Barkas, L | 1 |
| Redhead, E | 1 |
| Taylor, M | 1 |
| Shtaya, A | 1 |
| Hamilton, DA | 1 |
| Gray, WP | 1 |
| Heinen, M | 1 |
| Hettich, MM | 1 |
| Ryan, DP | 1 |
| Schnell, S | 1 |
| Paesler, K | 1 |
| Ehninger, D | 1 |
| Watson, SN | 1 |
| Risling, TE | 1 |
| Hermann, PM | 1 |
| Wildering, WC | 1 |
| Ledo, JH | 1 |
| Azevedo, EP | 1 |
| Clarke, JR | 1 |
| Ribeiro, FC | 1 |
| Figueiredo, CP | 1 |
| Foguel, D | 1 |
| De Felice, FG | 1 |
| Ferreira, ST | 1 |
| Joss, JD | 1 |
| Burton, RM | 1 |
| Keller, CA | 1 |
| El Hage, W | 1 |
| Peronny, S | 1 |
| Griebel, G | 1 |
| Belzung, C | 1 |
| Huang, SC | 1 |
| Tsai, SJ | 1 |
| Chang, JC | 1 |
| Gallassi, R | 1 |
| Di Sarro, R | 1 |
| Morreale, A | 1 |
| Amore, M | 1 |
| Spanswick, SC | 1 |
| Epp, JR | 2 |
| Keith, JR | 2 |
| Sutherland, RJ | 2 |
| Mowla, A | 1 |
| Mosavinasab, M | 1 |
| Pani, A | 1 |
| Wu, Y | 1 |
| Ibi, D | 1 |
| Takuma, K | 1 |
| Koike, H | 1 |
| Mizoguchi, H | 1 |
| Tsuritani, K | 1 |
| Kuwahara, Y | 1 |
| Kamei, H | 1 |
| Nagai, T | 1 |
| Yoneda, Y | 1 |
| Nabeshima, T | 1 |
| Yamada, K | 1 |
1 review available for fluoxetine and Memory Disorders
| Article | Year |
|---|---|
[Subjective cognitive complaint. From anxiety to prodromal Alzheimer's disease?].
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognition Diso | 2013 |
2 trials available for fluoxetine and Memory Disorders
| Article | Year |
|---|---|
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy.
Topics: Adolescent; Adult; Age of Onset; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Memor | 2006 |
Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial.
Topics: Aged; Cognition; Double-Blind Method; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Memory; M | 2007 |
28 other studies available for fluoxetine and Memory Disorders
| Article | Year |
|---|---|
Ameliorating effect offluoxetine on tamoxifen-induced memory loss: The role of corticolimbic NMDA receptors and CREB/BDNF/cFos signaling pathways in rats.
Topics: Amnesia; Animals; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Fl | 2022 |
Hippocampus Metabolic Disturbance and Autophagy Deficiency in Olfactory Bulbectomized Rats and the Modulatory Effect of Fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Autophagy; Depression; Disease Models, Animal; Fl | 2019 |
Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Female; Fluoxetine; Hippocampus; Male; Memory D | 2020 |
Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Food Pre | 2021 |
Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice.
Topics: Animals; Anti-Anxiety Agents; Antineoplastic Agents, Alkylating; Anxiety; Brain Diseases; Chemoradio | 2019 |
Galanin (1-15)-fluoxetine interaction in the novel object recognition test. Involvement of 5-HT1A receptors in the prefrontal cortex of the rats.
Topics: Animals; Drug Interactions; Fluoxetine; Galanin; Male; Memory Disorders; Neuropeptides; Peptide Frag | 2019 |
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Biophysics; Disease Models, | 2014 |
Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Dorsal Raphe | 2014 |
Single fluoxetine treatment before but not after stress prevents stress-induced hippocampal long-term depression and spatial memory retrieval impairment in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; CA1 Region, Hippocampal; Fl | 2015 |
Serotonin 6 receptor controls Alzheimer's disease and depression.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Pre | 2015 |
Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats.
Topics: Animals; CA1 Region, Hippocampal; Carotid Stenosis; Cerebrovascular Circulation; Cerebrovascular Dis | 2016 |
Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease | 2016 |
Fluoxetine prevents the memory deficits and reduction in hippocampal cell proliferation caused by valproic acid.
Topics: Animals; Cell Proliferation; Doublecortin Protein; Fluoxetine; Hippocampus; Male; Memory Disorders; | 2016 |
Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus.
Topics: Animals; Astrocytes; Avoidance Learning; Cell Death; Cyclooxygenase 2; Dose-Response Relationship, D | 2009 |
Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
Topics: Analysis of Variance; Animals; Cell Proliferation; Disease Models, Animal; Exploratory Behavior; Flu | 2010 |
Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bromodeoxyuridine; | 2011 |
Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Topics: Animals; Animals, Newborn; Brain; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cognition; | 2010 |
Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Cell Proliferation | 2011 |
Fluoxetine restores spatial learning but not accelerated forgetting in mesial temporal lobe epilepsy.
Topics: Adult; Animals; Epilepsy, Temporal Lobe; Female; Fluoxetine; Humans; Learning; Male; Maze Learning; | 2012 |
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Body Weight; Cell Count; Cognition Disorders; Down Syndrome; Female; Fluo | 2012 |
Failure of delayed nonsynaptic neuronal plasticity underlies age-associated long-term associative memory impairment.
Topics: Age Factors; alpha-Tocopherol; Analysis of Variance; Animals; Antioxidants; Appetitive Behavior; Avo | 2012 |
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Brain Chemistry; Cognition Disorders; | 2013 |
Memory loss in a patient treated with fluoxetine.
Topics: Aged; Aged, 80 and over; Female; Fluoxetine; Humans; Memory Disorders | 2003 |
Impaired memory following predatory stress in mice is improved by fluoxetine.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Diazepam; Exploratory Behavi | 2004 |
Fluoxetine-induced memory impairment in four family members.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Depressive Disorder, Major; Fe | 2004 |
Adrenalectomy-induced granule cell degeneration in the hippocampus causes spatial memory deficits that are not reversed by chronic treatment with corticosterone or fluoxetine.
Topics: Adrenalectomy; Animals; Biomarkers; Cell Count; Corticosterone; Cytoplasmic Granules; Doublecortin D | 2007 |
Fluoxetine and the dentate gyrus: memory, recovery of function, and electrophysiology.
Topics: Animals; Antidepressive Agents, Second-Generation; Colchicine; Dentate Gyrus; Drug Administration Sc | 2007 |
Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Behavior, Animal; Bromodeoxyuridine; Cell Pro | 2008 |